Medifast reported a net loss of $3.1 million, or $0.28 per diluted share, for the second quarter ended June 30, 2026, compared to net income of $2.5 million in the prior year period. Revenue declined 27.6% to $76.4 million from $105.6 million, driven by a 48.7% drop in active earning coaches to 11,700 amid pressure from GLP-1 medications. The company maintains a strong balance sheet with $169.8 million in cash and no debt. Medifast provided Q3 2026 revenue guidance of $60 million to $80 million and full-year revenue guidance of $270 million to $300 million, expecting a full-year loss per share between $0.25 and $1.75. The company operates in the health and wellness industry, offering metabolic health systems and coaching services.

On July 17, 2026, Medifast, Inc. announced the rebranding of its wholly-owned subsidiary, OPTAVIA, to Trilivy. This transformation shifts the company's focus from traditional weight loss to a comprehensive metabolic health system. The launch includes the Trilivy Reset Fueling line featuring MetaVantage Technology, with newly formulated meal replacements planned for debut in August. The system utilizes a three-phase approach—Reset, Refine, and Renew—and is supported by a network of independent coaches. Medifast operates in the health and wellness industry, providing science-backed metabolic health systems and meal replacements.